Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244563670> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4244563670 endingPage "1435" @default.
- W4244563670 startingPage "1429" @default.
- W4244563670 abstract "Therapy with tacrine, a promising new treatment for Alzheimer's disease, must be discontinued in up to 15% of patients because of hepatocellular toxicity. Recent studies using human liver microsomes have suggested that a single liver enzyme, cytochrome P450 1A2 (CYP1A2), catalyzes the major route of metabolism and elimination of tacrine, and also catalyzes the pathway(s) involved in the generation of reactive metabolites capable of covalent protein binding and cytotoxicity. Because CYP1A2 activity has been shown to vary up to 60- fold among patients, we proposed that a convenient measure of CYP1A2 activity, the [13C 3-methyl] caffeine breath test (CBT), might be clinically useful in identifying patients most susceptible to tacrine liver toxicity. To test this hypothesis, we administered the CBT to 37 patients with Alzheimer's disease before they began treatment with tacrine. Twenty patients received 2 mg/kg of [(13)C 3-methyl] caffeine. The remaining 17 patients received the commercially available CBT kit, which employs a constant 200-mg dose. The activities of two other major drug-metabolizing enzymes (cytochrome P450 3A4 and 2D6 [CYP3A4 and CYP2D6]) were also measured in these 17 patients. We found that the results obtained from the CBT protocol did not predict the peak serum alanine transaminase (ALT) observed in the patients. The measured CYP3A4 and CYP2D6 activities also failed to predict the susceptible patients. However, the result of the standardized-dose CBT correlated well with the logarithm of the steady-state plasma tacrine level obtained in 10 patients (R2 = .69, P = .003). We conclude that the CBT will not be clinically useful in determining the subset of patients most susceptible to tacrine hepatotoxicity. However, the correlation we observed between CBT results and tacrine blood levels is the first evidence supporting a critical role for CYP1A2 activity in the disposition of the drug in vivo." @default.
- W4244563670 created "2022-05-12" @default.
- W4244563670 creator A5060589711 @default.
- W4244563670 date "1996-06-01" @default.
- W4244563670 modified "2023-09-26" @default.
- W4244563670 title "The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity" @default.
- W4244563670 doi "https://doi.org/10.1053/jhep.1996.v23.pm0008675160" @default.
- W4244563670 hasPublicationYear "1996" @default.
- W4244563670 type Work @default.
- W4244563670 citedByCount "0" @default.
- W4244563670 crossrefType "journal-article" @default.
- W4244563670 hasAuthorship W4244563670A5060589711 @default.
- W4244563670 hasConcept C109650736 @default.
- W4244563670 hasConcept C126322002 @default.
- W4244563670 hasConcept C160160445 @default.
- W4244563670 hasConcept C181199279 @default.
- W4244563670 hasConcept C185592680 @default.
- W4244563670 hasConcept C2778500429 @default.
- W4244563670 hasConcept C2778606649 @default.
- W4244563670 hasConcept C2778816929 @default.
- W4244563670 hasConcept C2779046751 @default.
- W4244563670 hasConcept C2779679107 @default.
- W4244563670 hasConcept C29730261 @default.
- W4244563670 hasConcept C33664856 @default.
- W4244563670 hasConcept C526171541 @default.
- W4244563670 hasConcept C55493867 @default.
- W4244563670 hasConcept C62231903 @default.
- W4244563670 hasConcept C71924100 @default.
- W4244563670 hasConcept C86745063 @default.
- W4244563670 hasConcept C98274493 @default.
- W4244563670 hasConceptScore W4244563670C109650736 @default.
- W4244563670 hasConceptScore W4244563670C126322002 @default.
- W4244563670 hasConceptScore W4244563670C160160445 @default.
- W4244563670 hasConceptScore W4244563670C181199279 @default.
- W4244563670 hasConceptScore W4244563670C185592680 @default.
- W4244563670 hasConceptScore W4244563670C2778500429 @default.
- W4244563670 hasConceptScore W4244563670C2778606649 @default.
- W4244563670 hasConceptScore W4244563670C2778816929 @default.
- W4244563670 hasConceptScore W4244563670C2779046751 @default.
- W4244563670 hasConceptScore W4244563670C2779679107 @default.
- W4244563670 hasConceptScore W4244563670C29730261 @default.
- W4244563670 hasConceptScore W4244563670C33664856 @default.
- W4244563670 hasConceptScore W4244563670C526171541 @default.
- W4244563670 hasConceptScore W4244563670C55493867 @default.
- W4244563670 hasConceptScore W4244563670C62231903 @default.
- W4244563670 hasConceptScore W4244563670C71924100 @default.
- W4244563670 hasConceptScore W4244563670C86745063 @default.
- W4244563670 hasConceptScore W4244563670C98274493 @default.
- W4244563670 hasIssue "6" @default.
- W4244563670 hasLocation W42445636701 @default.
- W4244563670 hasOpenAccess W4244563670 @default.
- W4244563670 hasPrimaryLocation W42445636701 @default.
- W4244563670 hasRelatedWork W1980407312 @default.
- W4244563670 hasRelatedWork W1990441312 @default.
- W4244563670 hasRelatedWork W2007173515 @default.
- W4244563670 hasRelatedWork W2055543989 @default.
- W4244563670 hasRelatedWork W2061833569 @default.
- W4244563670 hasRelatedWork W2067772266 @default.
- W4244563670 hasRelatedWork W2308033060 @default.
- W4244563670 hasRelatedWork W2336312402 @default.
- W4244563670 hasRelatedWork W2360475668 @default.
- W4244563670 hasRelatedWork W3190655411 @default.
- W4244563670 hasVolume "23" @default.
- W4244563670 isParatext "false" @default.
- W4244563670 isRetracted "false" @default.
- W4244563670 workType "article" @default.